JP2007001922A - Renal disease ameliorating agent in dialysis patient or functional food - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a renal disease improving agent in dialysis patients, an agent for preventing and/or improving arteriosclerosis in dialysis patients or a functional food, and furthermore an application method using them. <P>SOLUTION: The renal disease improving agent in dialysis patients and the agent for preventing and/or improving arteriosclerosis in dialysis patients contain coenzyme Q10 as an active ingredient. The functional food having a renal disease improving effect in dialysis patients and a preventing and/or improving effect on arteriosclerosis in dialysis patients contains the compound as an active ingredient. Coenzyme Q10 is used in preparing a composition for improving the renal disease in dialysis patients and for preventing and/or improving the arteriosclerosis in dialysis patients. A method of improving the renal disease in dialysis patients and a method of preventing and/or improving the arteriosclerosis in dialysis patients comprise taking in a composition containing the compound as an active ingredient. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a preventive and / or ameliorating agent for symptoms or diseases caused by oxidative stress in dialysis patients, characterized by containing coenzyme Q10 as an active ingredient. In particular, it relates to a renal disease ameliorating agent or a functional food. The present invention also relates to the use of coenzyme Q10 for producing a composition for improving renal disease in dialysis patients and the use of coenzyme Q10 for improving renal disease in dialysis patients. Alternatively, the present invention relates to an agent for preventing and / or improving arteriosclerosis characterized by containing coenzyme Q10 as an active ingredient, which is used in combination with a vitamin E-immobilized hollow fiber membrane dialyzer.

  Coenzyme Q10 is a benzoquinone derivative and is widely distributed in the living world, so it was named ubiquinone (oxidized coenzyme Q10). A hydroquinone form obtained by reducing this by two electrons is ubiquinol (reduced coenzyme Q10). Although many homologues exist depending on the length (n) of the isoprenoid side chain (n = 1 to 12), the main homologue is determined by the species because it is biosynthesized. In mammals, n = 9 and 10 are mainly used. For example, n = 9 is often used in mice and rats, and n = 10 is often used in rabbits. For humans, n = 10.

  Coenzyme Q10 is a physiological component that exists as a constituent component of the mitochondrial electron transfer system in cells in the living body, and plays a role as a transfer component in the electron transfer system by repeating oxidation and reduction in the living body. Since coenzyme Q10 exhibits energy production and antioxidant activity in vivo, its usefulness is widely known. Coenzyme Q10 is a molecule that is biosynthesized in the human body, but it has been reported that the amount of biosynthesis decreases with age, or that the amount of coenzyme Q10 in the body in various diseases is decreased. In such diseases, external supply of coenzyme Q10 has yielded good results. Furthermore, it is considered that coenzyme Q10 needs to be replenished not only at the time of illness but also at normal times such as when the elderly or physically fatigued.

  Oxidized coenzyme Q10 is used for pharmaceutical use as a congestive heart failure drug. In addition to vitamins, as with vitamins, nutritional supplements, nutritional supplements, senile diseases such as dementia, usefulness for allergic diseases, and increased exercise capacity have also been reported, and their safety It is said to be a useful means of nutrition because it is expensive.

  Currently, about 240,000 people are receiving dialysis therapy in Japan, and about 30,000 new dialysis therapy is started every year. The number of patients receiving dialysis therapy is expected to increase in the future as the number of elderly people increases and the number of diabetic patients increases.

  In long-term dialysis patients, it is known that the incidence of dialysis amyloidosis, arteriosclerotic disease, etc. is increasing as a complication. This is probably because the dialysis membrane used in dialysis therapy is recognized as a xenobiotic and leukocytes and platelets are adsorbed to the membrane, and at this time, many free radicals are produced and the blood is in a high oxidative stress state. That is, in patients receiving dialysis therapy for a long time, a decrease in blood antioxidant action, a high level of lipid peroxide, and the like have been confirmed (Non-patent Document 1). Therefore, it has been pointed out that suppressing oxidative stress experienced by dialysis patients has a high possibility of improving the patient's QOL (Quality of Life) and prognosis.

In order to solve such problems, an immobilized hollow fiber membrane type in which the surface of a dialysis membrane is coated with a coating of vitamin E having various physiological actions such as in vivo antioxidant action, biological membrane stabilization action, and platelet aggregation inhibition action. A dialyzer was developed. Vitamin E is known to most efficiently supplement lipid peroxide, a precursor of lipid peroxide, in vivo. However, vitamin E itself is oxidized in the reaction of reducing lipid peroxide to become vitamin E radicals. Since this vitamin E radical does not have an antioxidant ability, in order to continuously eliminate the lipid peroxide, it is necessary to reduce the vitamin E radical and return it to vitamin E that can supplement the lipid peroxide. That is, dialysis using a vitamin E-immobilized hollow fiber membrane dialyzer is still insufficient, and a method for protecting further blood from oxidative stress has been desired.
Against this background, development of a renal disease ameliorating agent or functional food for dialysis patients has been strongly desired.
Osamu Nishikawa, Hyperlipidemia in dialysis patients, Japanese clinical practice, (2001) 59, (3), 753-757

  An object of the present invention is to provide a preventive and / or ameliorating agent for symptoms or diseases caused by oxidative stress on dialysis patients. In particular, it is to provide a renal disease ameliorating agent for dialysis patients, an arteriosclerosis prevention and / or ameliorating agent for dialysis patients, or a functional food, and further provide an application method using them.

As a result of intensive studies to solve the above problems, the present inventors have found that coenzyme Q10 has an effect of improving renal disease in dialysis patients. Specifically, by ingesting or applying a composition containing Coenzyme Q10 as an active ingredient in combination with a vitamin E-immobilized hollow fiber membrane dialyzer, treatment of renal disease in dialysis patients without any side effects, or The present invention has been completed by finding an improvement.
That is, the present invention has the following configuration.
(1) A renal disease ameliorating agent in a dialysis patient containing coenzyme Q10 as an active ingredient.
(2) A preventive or ameliorating agent for symptoms or diseases caused by oxidative stress containing coenzyme Q10 as an active ingredient, used in combination with a vitamin E-immobilized hollow fiber membrane dialyzer.
(3) One or more symptoms or diseases caused by oxidative stress are selected from the group consisting of fatigue, aging, skin degeneration, heart disease, liver disease, brain disease, renal disease, arteriosclerosis, diabetes and these complications The preventive and / or ameliorating agent according to (2) above, wherein
(4) A functional food having an effect of improving renal disease in dialysis patients containing coenzyme Q10 as an active ingredient.
(5) Use of coenzyme Q10 for producing a composition for improving renal disease in dialysis patients.
(6) Use of coenzyme Q10 to improve renal disease in dialysis patients.
(7) A method for improving renal disease in a dialysis patient, comprising ingesting a composition containing coenzyme Q10 as an active ingredient.
(8) A method for preventing or treating a symptom or disease caused by oxidative stress, comprising using a composition containing coenzyme Q10 as an active ingredient in combination with a vitamin E-immobilized hollow fiber membrane dialyzer.
(9) One or more symptoms or diseases caused by oxidative stress are selected from the group consisting of fatigue, aging, skin degeneration, heart disease, liver disease, brain disease, renal disease, arteriosclerosis, diabetes and these complications The prevention or treatment method according to (8) above, wherein
(10) A vitamin E-immobilized hollow fiber membrane dialyzer used in combination with a composition containing coenzyme Q10 as an active ingredient.

  According to the present invention, it has a preventive and / or ameliorating agent for symptoms or diseases caused by oxidative stress characterized by containing coenzyme Q10 as an active ingredient, and has a preventive and / or ameliorating effect on symptoms or diseases caused by oxidative stress Use of functional foods, cosmetics, and further coenzyme Q10 for preparing a composition for preventing and / or improving symptoms or diseases caused by oxidative stress, and ingesting a composition containing the compound as an active ingredient It is possible to provide a method for preventing and / or improving symptoms or diseases caused by oxidative stress.

  The present invention will be specifically described below. Coenzyme Q10 used in the present invention is not limited in its origin and production method as long as it is coenzyme Q10 that can be taken or edible as a medicine or food, but a commercially available product is preferred. Further, it may be a compound that converts to coenzyme Q10 in vivo.

  The content of coenzyme Q10 in medicines and foods is not limited as long as it is an amount that can prevent and / or improve symptoms or diseases caused by oxidative stress, but daily intake of coenzyme Q10 The amount is such that the amount is 1 to 2000 mg, preferably 10 to 500 mg, more preferably 30 to 300 mg.

  Coenzyme Q10 is a lipophilic solid having a low melting point, and is known to have low absorbability in oral administration due to poor solubility in water. For this reason, it is preferable to improve stability of properties such as dispersion stability of coenzyme Q10 in pharmaceutical preparations and foods, and prevention of crystal precipitation, and bioabsorbability. In the present invention, a stabilized product of coenzyme Q10 may be used. For example, coenzyme Q10 is blended with animal protein such as chicken egg protein, milk protein, meat protein, vegetable protein such as soy protein or soy peptide, or a hydrolyzate thereof, or further blended with sugar such as starch. By doing so, it may be used after coenzyme Q10 is stabilized and bioabsorbability is further improved.

  When coenzyme Q10 is used as an emulsified composition, for example, coenzyme Q10 is dissolved in a sucrose fatty acid ester such as sucrose acetate isobutyric acid ester, poly (mono) glycerol fatty acid ester, etc. as an oil phase component, and a polyhydric alcohol and an emulsifier Or gum arabic, agar, water-soluble corn fiber, starch, gelatin, xanthan gum, casein, dextrin, carmelol sodium, polyvinylpyrrolidone in the presence or absence of additives such as organic acids Coenzyme Q10 may be dispersed and emulsified in a water-soluble substance such as, or incorporated into an inclusion compound such as cyclodextrin and then used after improving the stability of properties and bioabsorbability.

  The subject who receives the preventive and / or ameliorating agent, composition or food for symptoms or diseases caused by oxidative stress according to the present invention is a human or an animal. In the present invention, animals refer to industrial animals, companion animals, and experimental animals. Industrial animals include domestic animals such as cattle, horses, pigs, goats, and sheep, poultry such as chickens, ducks, quails, turkeys, and ostriches, and fish such as yellowtail, yellowtail, red sea bream, red sea bream, carp, rainbow trout, and eels. It is an animal that is needed to do. The companion animal refers to animals commonly used for research in the fields of medicine, biology, agriculture, pharmacology, such as dogs, cats, marmosets, beagle dogs, minipigs, rhesus monkeys, and cynomolgus monkeys.

  The symptom or disease caused by oxidative stress as a target of the present invention is not limited as long as it is a symptom or disease caused by oxidative stress. Symptoms or diseases caused by oxidative stress include fatigue, aging, skin degeneration, heart disease, liver disease, brain disease, kidney disease, arteriosclerosis, diabetes, allergy, rheumatic disease, cancer, AIDS, Parkinson's disease, Alzheimer type Examples include dementia, diabetic retinopathy, cataract, myocardial infarction, cerebral infarction, hypertension, gastric ulcer, ischemic enteritis, chronic pancreatitis, renal failure and uremia.

  The composition of the present invention may be a physical fatigue improving agent or an energy production activator. The physical fatigue improving agent includes a physical fatigue preventing agent, and an agent for reducing physical fitness during pregnancy / lactation and after sickness. An energy production activator has the effect | action which improves the cell activity which received the oxidative stress disorder | damage | failure by exercise and aging.

  In addition, the kidney disease that is the subject of the present invention is not limited as long as it is a kidney disease. Renal diseases are divided into two types: diseases caused by abnormalities in the kidneys themselves and diseases in which the kidneys malfunction due to abnormalities or changes in organs other than the kidneys.

  In diseases caused by abnormalities in the kidney itself, abnormalities appear in any or all of the glomeruli, tubules, stroma (connective tissue), and blood vessels that make up the kidney. Diseases caused by abnormalities in the kidney itself are divided into hereditary and acquired. Examples of hereditary diseases include multiple cystic kidneys and hereditary nephritis. Acquired diseases include glomerulonephritis, tubules / intervals. Examples include diseases caused by stones such as interstitial nephritis, pyelonephritis, cystitis, kidney tuberculosis, kidney stones, and ureteral stones, and diseases caused by cancers such as kidney cancer and bladder cancer.

  Examples of diseases in which the kidneys are impaired due to abnormalities or changes in organs other than the kidney include various renal diseases such as renal diseases caused by metabolic diseases and renal diseases related to blood diseases. Examples of renal diseases caused by metabolic diseases include diabetic nephropathy, gout kidney, and amyloid kidney. Examples of renal diseases caused by hematological diseases include multiple myeloma kidney caused by multiple myeloma, hemolytic uremic toxin. Syndrome, nephrosclerosis due to hypertension, etc., and other examples include lupus nephritis due to collagen disease, hepatic glomerulosclerosis due to chronic liver disease, and the like. There are three typical symptoms of these kidney diseases: abnormal urine, swelling (edema), and hypertension.

  In kidney disease, the kidney function is less than 30% of normal due to abnormal renal function, and the state in which waste and excess water in the body cannot be excreted is called renal failure, and further renal failure progresses with subjective symptoms What has become known is called uremia, and the patient who developed the uremic disease is receiving dialysis therapy.

  The composition containing coenzyme Q10 of the present invention as an active ingredient may be any composition that is effective for preventing and / or improving symptoms or diseases caused by oxidative stress by ingestion. A method for preventing and / or improving a symptom or disease caused by oxidative stress characterized by ingesting the composition is also within the scope of the present invention. Ingestion includes both oral and parenteral, and parenteral includes application, injection, infusion, and nasal administration.

  The use of coenzyme Q10 of the present invention is not particularly limited as long as it is used for preparing a composition for preventing and / or improving symptoms or diseases caused by oxidative stress. The composition effective for preventing and / or ameliorating symptoms or diseases caused by oxidative stress includes a drug as an agent for preventing and / or improving symptoms or diseases caused by oxidative stress, and symptoms or diseases caused by oxidative stress. Functional foods having a preventive and / or improving effect, cosmetics and the like.

  The pharmaceutical containing coenzyme Q10 of the present invention is not limited in any way as long as it can prevent and / or improve the symptoms or diseases caused by oxidative stress. The pharmaceutical dosage form includes scattered, granule, pill, soft capsule, hard capsule, tablet, chewable tablet, quick-disintegrating tablet, syrup, liquid, suspension, suppository, ointment, cream, gel, sticky Agents, inhalants, injections and the like. These preparations are prepared according to conventional methods. However, since Coenzyme Q10 is hardly soluble in water, it can be dissolved in non-hydrophilic organic solvents such as vegetable oils and animal oils, or emulsifiers, dispersants or surfactants. Along with the agent, etc., it is used after being dispersed and emulsified in an aqueous solution using a homogenizer (high pressure homogenizer). Furthermore, in order to increase the absorbability of coenzyme Q10, the average particle system can be finely pulverized to about 1 micron.

  Additives that can be used for formulation include animal oils such as soybean oil, safflower oil, olive oil, germ oil, sunflower oil, beef tallow, sardine oil, polyethylene glycol, propylene glycol, glycerin, sorbitol, etc. Surfactant such as polyhydric alcohol, sorbitan fatty acid ester, sucrose fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, purified water, lactose, starch, crystalline cellulose, D-mannitol, lecithin, gum arabic, sorbitol solution, sugar Examples thereof include excipients such as liquid, sweeteners, colorants, pH adjusters, and fragrances. The liquid preparation may be dissolved or suspended in water or other appropriate medium when taken. Tablets and granules may be coated by a known method.

  When administered in the form of an injection, it can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, transdermally, intraarticularly, within the bursa, intravesicular, intraperiosteally, sublingually, orally. In particular, intravenous administration or intraperitoneal administration is preferred. Intravenous administration may be either drip administration or porous administration.

  The functional food containing coenzyme Q10 of the present invention is not limited in any way as long as the effect of ameliorating symptoms or diseases caused by oxidative stress is obtained. For example, a coenzyme Q10-containing supplement (scattered, granule) , Soft capsules, hard capsules, tablets, chewable tablets, quick-disintegrating tablets, syrups, liquids, etc., beverages containing coenzyme Q10 (tea, carbonated beverages, lactic acid beverages, sports drinks, etc.), confectionery containing coenzyme Q10 (gummy, jelly, gum, chocolate) , Cookies, candy, etc.), oil containing coenzyme Q10, fat and oil food containing coenzyme Q10 (mayonnaise, dressing, butter, cream, margarine, etc.) coenzyme Q10 containing ketchup, coenzyme Q10 containing sauce, coenzyme Q10 containing liquid food, coenzyme Q10-containing dairy products (milk, yogurt, cheese, etc.), Coenzyme Q10-containing bread, coenzyme Q10-containing noodles (udon, soba, ramen, pasta, fried noodle, noodles, somen, hiyamugi, vermicelli, etc.) and the like.

  The functional food containing coenzyme Q10 used in the present invention includes various nutrients, various vitamins (vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E as necessary. , Vitamin K, etc.), various minerals (magnesium, zinc, iron, sodium, potassium, selenium, titanium oxide, etc.), dietary fiber, sugars (cellulose, dextrin, chitin, etc.), polyunsaturated fatty acids (arachidonic acid, docosahexaene) Acid, eicosapentaenoic acid, docosapentaenoic acid, etc.), conjugated fatty acids (conjugated linoleic acid, etc.), phospholipids (lecithin, phosphatidic acid, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylcholine, phosphatidylinositol) , Phosphatidyl DHA, etc.), glycolipids (such as cerebroside), carotenoids (such as β-carotene, lycopene, astaxanthin, β-cryptoxanthin), flavonoids (such as quercetin, luteolin, isoflavone), xanthophylls (capsanthin, lutein, etc.) Zeaxanthin), amino acids (glycine, serine, alanine, glutamine, valine, leucine, isoleucine, lysine, arginine, aspartic acid, glutamic acid, tryptophan, phenylalanine, histidine, proline, methionine, cysteine, etc.), other nutrients (carnitine, Sesamin, α-lipoic acid, inositol, D-kaileunositol, pinitol, taurine, glucosamine, chondroitin sulfate, S-adnosylmethionine, curcumin, γ-o Zanol, glutathione, γ-aminobutyric acid, synephrine, pyrroloquinoline quinone, catechin, capsaicin, etc., stabilizers such as dispersants, emulsifiers, sweeteners (sorbitol, sucrose, etc.), taste ingredients (citric acid, malic acid, etc. ), Flavor, royal jelly, honey, beeswax, propolis, agarics and the like. Moreover, you may mix | blend herbs, such as peppermint, bergamot, camomile meal, and lavender. Moreover, you may mix | blend raw materials, such as theanine, a dehydroepiandosterone, and melatonin. Moreover, there is no problem even if reduced coenzyme Q10 produced from oxidized coenzyme Q10 is contained in the process of processing as food or cosmetics due to physical conditions or other coexisting components.

  Examples of the cosmetic of the present invention include creams, emulsions, lotions, microemulsion essences, bathing agents, and the like, and fragrances and the like may be mixed.

  The method for evaluating the degree of prevention and / or improvement of symptoms or diseases caused by oxidative stress may be any method for evaluating the degree of prevention and / or improvement of symptoms or diseases caused by oxidative stress. The method of measuring is mentioned. The oxidative stress marker is not limited as long as it is an oxidative stress marker. For example, oxidized LDL, CRP, 8-hydroxydeoxyguanosine, FRAS, lipid peroxide, malondialdehyde, carboxymethyllysine, pentosidine, hexanoyl Examples include oxidation rates of lysine, 4-hydroxynonenal, acrolein, coenzyme Q10, and oxygen activity values such as glutathione peroxidase, superoxide dismutase, and catalase.

The vitamin E-immobilized hollow fiber membrane type dialyzer used in the present invention is not limited as long as it is a dialyzer in which vitamin E is immobilized.
The dialyzer of the present invention has a function of removing waste products from the blood by removing them from the blood by the action of dialysis and filtration through body fluid treatment membranes such as dialysis membranes and blood filtration membranes. Specific examples include those having micropores of several μm, and specifically, hemodialyzers, hemofilters, simultaneous hemodialyzers, plasma separators, plasma fraction filters, and the like. Examples of the material of the hollow fiber membrane used include polyethylene, polymethyl methacrylate, polystyrene, polypropylene, polysulfone, polyhydroxyethyl methacrylate, nylon 66, polyacrylonitrile, polyvinyl alcohol, ethylene-vinyl alcohol copolymer, polycarbonate, and the like. . Examples of the cellulose material include regenerated cellulose, saponified cellulose, cellulose diacetate, cellulose triacetate, and diethylaminoethyl cellulose. Furthermore, the hollow fiber membrane materials may be used alone or in combination of two or more. Moreover, the surface on which the antioxidant substance of the present invention is coated may be modified with a reactive monomer, a polymer compound or the like on the material of the hollow fiber membrane.

  As the form of the hollow fiber membrane, the inner diameter is 10 μm to 1000 μm, preferably 100 μm to 300 μm, the film thickness is 5 μm to 100 μm, preferably 20 μm to 60 μm, and even a non-uniform membrane partially having a dense layer in the cross section of the membrane, A uniform film having no dense layer may be used.

Vitamin E used in the present invention includes α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, γ-tocotrienol, α-tocopherol acetate, β- There are tocopherol acetate, γ-tocopherol acetate, δ-tocopherol acetate, α-tocopherol α-nicotinate, tocopherol β-nicotinate, tocopherol γ-nicotinate, and tocopherol δ-nicotinate. Vitamin E is more suitable because it has an electron-contributing property to coenzyme Q and, when combined, improves antioxidant properties. Among them, α-tocopherol is particularly preferable because it has various physiological actions such as in vivo antioxidant action, biological membrane stabilizing action, and platelet aggregation inhibitory action.
The coating amount of vitamin E on the hollow fiber is preferably 1 mg / m ² to 1000 mg / m ² . More preferably, it is 50 mg / m ² to 300 mg / m ² .
The case where the inner surface of the hollow fiber membrane of the hemodialyzer is coated with vitamin E will be described as an example. A vitamin E solution composed of vitamin E and a vitamin E solvent is prepared, and this is introduced into the lumen of the hollow fiber membrane, thereby attaching vitamin E to the inner surface of the hollow fiber membrane. As an inflow method, for example, a method of introducing a vitamin E solution for coating from the header nozzle of the hemodialyzer into the hollow fiber lumen using a circulation pump is simple.

[Reference example]
Method for preparing vitamin E-immobilized dialyzer Using 10,300 polysulfone hollow fiber membranes having an inner diameter of about 200 μm, an outer diameter of about 280 μm, a pore diameter (inner surface of 500 nm), and a length of about 24 cm, as shown in FIG. Inserted into the main body 4, both ends were fixed with polyurethane potting agents 6, 7, headers 10, 11 were attached to both ends, and fixed with caps 12, 13 to create a dialyzer (artificial kidney) 1. The dialyzer 1 had a membrane area of 1.5 m ² . The coating amount of the hollow fiber of vitamin E was 70 mg / m ² (Japanese Patent Laid-Open No. 11-178919).

  The present invention will be described based on formulation examples, food production examples, cosmetic production examples, and examples, but the present invention is not limited to the following examples.

[Formulation Example 1]
<Tablets>
Coenzyme Q10 120g
Crystalline cellulose 330g
Carmellose-calcium 15g
Hydroxypropylcellulose 10g
60 ml of purified water
The above composition was blended and dried in the usual manner, 10 g of magnesium stearate was added, and tableting was performed to obtain 100 mg tablets containing 20 mg of coenzyme Q10 per tablet.

[Formulation Example 2]
<Soft capsule>
200 g of coenzyme Q10 was added to 400 g of olive oil, dissolved at about 60 ° C., stirred uniformly, and then cooled to obtain a coenzyme Q10-containing material. Gelatin 70% and glycerin 30% were mixed and swollen to prepare a dissolved gelatin sheet. This gelatin sheet was filled with a coenzyme Q10-containing material as an internal solution so as to have an internal volume of 300 mg per capsule and dried to obtain soft capsules containing 100 mg of coenzyme Q10 per capsule.

[Food Production Example 1]
<Beverage>
30 g of coenzyme Q10 was heated to 60 ° C. to obtain an oil phase. 10 g of glycerol fatty acid ester as an emulsifier was added to 90 g of glycerin and heated to 70 ° C. to dissolve. The previous oil phase is gradually added to this solution with stirring. The mixed solution was subjected to high-pressure emulsification using an emulsifier to obtain an emulsified composition. To 20 g of this emulsified composition, 180 ml of water was added and stirred to obtain a coenzyme Q10-containing beverage.

[Food Production Example 2]
<Bread>
1 g of coenzyme Q10, 15 g of sugar, 2 g of salt and 5 g of fat powdered milk were dissolved in 70 g of hot water, and 2 eggs were added and mixed well. This was added to a mixture of 130 g of wheat flour and 2 g of dry yeast, kneaded by hand, then kneaded with about 30 g of butter to make 30 roll bread dough. Next, after fermenting, a beaten egg was applied to the surface and baked in an oven at 180 ° C. for 15 minutes to obtain a roll.

[Food Production Example 3]
<Udon>
To 400 g of wheat flour, 2 g of coenzyme Q10 and 20 g of sodium chloride were added to 200 g of water and kneaded well. Thereafter, the dough was stretched and cut into widths of about 6 mm to produce udon.

[Cosmetics Production Example 1]
<Cream>
Coenzyme Q10, stearyl alcohol, propylene glycol, sorbitol, paraben, vitamin E, fragrance, and purified water were blended in appropriate amounts according to a conventional method to obtain a cream.

[Example 1]
<Administration of coenzyme Q10 to patients undergoing dialysis treatment using a dialyzer that does not immobilize vitamin E>
The following tests were performed using PS membrane, PMMA membrane (Toray), cellulose acetate (Nipro), PEPA (Nikkiso), EVAL membrane (Kuraray), etc. as a dialyzer not immobilizing vitamin E.
In this test, a soft capsule (formulation example 2) containing 100 mg of coenzyme Q10 was used as a composition containing coenzyme Q10 (100 mg).
Six patients undergoing dialysis with renal disease were given a coenzyme Q10-containing (100 mg) soft capsule every 2 months after dinner, and the oxidized LDL was measured as an oxidative marker before and 1 and 2 months after the start of administration. . The results are shown in Table 1. The oxidized LDL value of patients taking coenzyme Q10 was clearly improved after taking compared to before taking (Table 1).

[Example 2]
<Administration of coenzyme Q10 to a patient undergoing dialysis treatment using a vitamin E-immobilized hollow fiber membrane type riser>
In this test, a soft capsule (formulation example 2) containing 100 mg of coenzyme Q10 was used as a composition containing coenzyme Q10 (100 mg).
Six patients undergoing dialysis using a dialyzer prepared according to the reference example were to take a coenzyme Q10-containing (100 mg) soft capsule every 2 months after dinner, and oxidize before taking and after taking 1 or 2 months after taking Oxidized LDL was measured as a marker. The results are shown in Table 1. The oxidized LDL value of patients taking coenzyme Q10 was clearly improved compared to patients not taking coenzyme Q10 (Table 2). The oxidized LDL value of patients taking coenzyme Q10 was clearly improved after taking compared to before taking (Table 2). A comparison of Example 1 and Example 2 shows that the oxidized LDL value is improved in Example 2, so that more oxidative stress can be obtained by taking Coenzyme Q10 in combination with a dialyzer immobilized with vitamin E. Can be seen to be reduced.

  A functional food having an effect of improving renal disease in dialysis patients characterized by containing coenzyme Q10 of the present invention as an active ingredient can be suitably used in the field of medicine and / or food.

It is a perspective view which has a partial defect | deletion of the dialyzer which shows the reference example of this invention.

Explanation of symbols

DESCRIPTION OF SYMBOLS 1 Dialyzer 2 Dialysate inlet pipe 3 Dialysate outlet pipe 4 Tubular main body 5 Hollow fiber membrane 6 Potting agent 7 Potting agent 8 Body fluid inlet 9 Body fluid outlet 10 Header 11 Header 12 Cap 13 Cap 14 Tube 15 Tube 16 Hollow fiber membrane 17 Coating

Claims (10)

  An agent for improving renal disease in dialysis patients, comprising coenzyme Q10 as an active ingredient.   A preventive or ameliorating agent for symptoms or diseases caused by oxidative stress, comprising coenzyme Q10 as an active ingredient, used in combination with a vitamin E-immobilized hollow fiber membrane dialyzer.   One or more symptoms selected from the group consisting of fatigue, aging, skin degeneration, heart disease, liver disease, brain disease, kidney disease, arteriosclerosis, diabetes, and complications thereof are caused by oxidative stress or The preventive and / or ameliorating agent according to claim 2, which is a disease.   A functional food having an effect of improving renal disease in dialysis patients containing coenzyme Q10 as an active ingredient.   Use of coenzyme Q10 for producing a composition for ameliorating renal disease in a dialysis patient.   Use of coenzyme Q10 to improve renal disease in dialysis patients.   A method for improving renal disease in a dialysis patient, which comprises ingesting a composition containing coenzyme Q10 as an active ingredient.   A method for preventing or treating a symptom or disease caused by oxidative stress, comprising using a composition containing coenzyme Q10 as an active ingredient in combination with a vitamin E-immobilized hollow fiber membrane dialyzer.   One or more symptoms selected from the group consisting of fatigue, aging, skin degeneration, heart disease, liver disease, brain disease, kidney disease, arteriosclerosis, diabetes, and complications thereof are caused by oxidative stress or The method for prevention or treatment according to claim 8, which is a disease.   A vitamin E-immobilized hollow fiber membrane dialyzer that is used in combination with a composition containing coenzyme Q10 as an active ingredient.

Images